SILLAJEN RCC
22 Dec 2020
JX594-REN026
NCT03294083
A study of recombinant vaccinia virus in combination with REGN2810 for renal cell carcinoma
SillaJen, Inc.
Cancer Type | Kidney |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Renal Cell Carcinoma |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2018-06-07 |
Anticipated End Date | 2020-09-01 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | - |
Recruitment Status | Recruiting |